This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Stocks Poised to Trounce Market on Coronavirus Scare
by Urmimala Biswas
Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.
Moderna (MRNA) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is Moderna (MRNA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Moderna (MRNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Mallinckrodt Completes NDA Submission for Kidney Failure Drug
by Zacks Equity Research
Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection
by Kinjel Shah
A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.
Moderna Up as First Human Trial of Coronavirus Vaccine Begins
by Zacks Equity Research
Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.
4 Stocks That Will Survive the Coronavirus Collapse
by Nilanjan Banerjee
Although the Wall Street's 11-year bull run has come to a halt abruptly, it doesn't signify the end for all.
Company News for Mar 17, 2020
by Zacks Equity Research
Companies In The News Are: BNTX, MRNA, UAL, AAL.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
Gilead Up as Remdesivir Shows Promise in Treating Coronavirus
by Zacks Equity Research
Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
4 Top Biotech Stocks to Buy in the Time of Coronavirus
by Tirthankar Chakraborty
We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.
The Zacks Analyst Blog Highlights: Netflix, Microsoft, Sempra Energy, Co-Diagnostics and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Microsoft, Sempra Energy, Co-Diagnostics and Moderna
Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up
by Kaibalya Pravo Dey
While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
5 Smart Ways to Profit From the Coronavirus Crisis
by Tirthankar Chakraborty
Even though majority of investors are in a state of shock, many know how to profit during uncertain times like these. Here're five ways you can put your money to work amid the coronavirus outbreak.
Beat Virus With 2 Sector ETFs & Stocks That Survived 2008 Crisis
by Sanghamitra Saha
These two sectors lost lesser than the broader market during the 2008 financial crisis and may help you to tide over the latest virus crisis.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
5 of the Best Coronavirus-Proof Stocks to Invest In Now
by Sreoshi Bera
With coronavirus cases on the rise, lack of labor and supply chain disruption are impacting businesses worldwide. However, certain industries could offer healthy returns on investment.
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals
5 Stocks to Win Big From Trump's Economic Stimulus
by Tirthankar Chakraborty
Trump floats financial aids to counter the impact of the coronavirus outbreak. Notable stimulus measures include payroll tax cut, aid for wage earners and an emergency funding worth $8.3 billion
LabCorp (LH) Launches Test to Detect Presence of Coronavirus
by Zacks Equity Research
LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
Regeneron (REGN) Gains from Focus on Coronavirus Treatments
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.